Targeted Disruption of Inducible Nitric Oxide Synthase Protects Against Aging, S-Nitrosation, and Insulin Resistance in Muscle of Male Mice
Accumulating evidence has demonstrated that S-nitrosation of proteins plays a critical role in several human diseases. Here, we explored the role of inducible nitric oxide synthase (iNOS) in the S-nitrosation of proteins involved in the early steps of the insulin-signaling pathway and insulin resistance in the skeletal muscle of aged mice. Aging increased iNOS expression and S-nitrosation of major proteins involved in insulin signaling, thereby reducing insulin sensitivity in skeletal muscle. Conversely, aged iNOS-null mice were protected from S-nitrosation–induced insulin resistance. Moreover, pharmacological treatment with an iNOS inhibitor and acute exercise reduced iNOS-induced S-nitrosation and increased insulin sensitivity in the muscle of aged animals. These findings indicate that the insulin resistance observed in aged mice is mainly mediated through the S-nitrosation of the insulin-signaling pathway.
In recent decades, S-nitrosation, the reaction of nitric oxide (NO) with cysteine residues in proteins to form S-nitrosothiol adducts, in addition to phosphorylation, acetylation, and ubiquitination, has become one of the main forms of post-translational modification of intracellular eukaryotic proteins (1). Deregulated S-nitrosation contributes to a range of chronic human diseases (1,2).
NO donor agents and the NO produced by inducible NO synthase (iNOS) induces insulin resistance through the S-nitrosation of proteins involved in the early steps of insulin action, such as insulin receptor β (IRβ), insulin receptor substrate 1 (IRS-1), and Akt (3–5). Although several studies suggest that NO and iNOS could be involved in several aging-related diseases (2,6), the participation of these molecules on aging-induced insulin resistance is unclear. Here, we hypothesized that iNOS could mediate the insulin resistance through the S-nitrosation of insulin-signaling pathway proteins during aging.
RESEARCH DESIGN AND METHODS
Male C57BL/6 and iNOS-null mice were purchased from Jackson Laboratory (C57BL/6-Nos2tm1Lau colony), aged 3 months (young) and 28 months (old). Animals had free access to standard rodent chow and water. All experiments were approved by the ethics committee of the State University of Campinas.
L-N6-(l-iminoethyl) lysine (L-NIL) treatment.
The animals received an intraperitoneal injection of L-NIL (80 mg/kg body weight) or PBS, twice daily for 5 days (n = 8).
The animals swam in for two 1.5-h-long bouts, separated by a 30-min rest period (n = 8), in water maintained at ∼34°C. This exercise protocol was adapted from a previously published procedure (7).
Glucose and serum insulin quantification.
Serum insulin concentration was determined using a commercially available enzyme linked immunosorbent assay kit (Crystal Chem Inc.; n = 12). Fasting glucose was measured using Accutrend Plus equipment (Roche); in this case, the blood sample was obtained from the tails of mice (n = 12).
After a 6-h fast, the mice (n = 8) were anesthetized with a mixture of ketamine (100 mg) and diazepam (0.07 mg; 0.2 mL/100 g body weight). A 120-min hyperinsulinemic-euglycemic clamp procedure was conducted continuously infused at a rate of 5.0 mU/kg body weight ⋅ min to raise the plasma insulin concentration to ∼4.8–5.4 ng/mL. Glucose (5%) was infused at variable rates to maintain plasma glucose at 100 ± 10 mg/dL.
Glucose uptake measurement.
The glucose uptake in isolated soleus muscle was performed as previously described (3). At 1 h after the last L-NIL injection and 8 h after the exercise protocol, the mice (n = 8) were anesthetized and soleus muscles were isolated and incubated in Krebs-Ringer bicarbonate buffer and 0.011 MBq/mL d-[U-14C]glucose, with 95% O2/5% CO2, at 37°C and centrifuged at 1,000g. Incubation was performed for 1 h in the presence of 10 mUI/mL insulin and 2 or 20 mmol/L glutamine. Uptake of 2-deoxy-d-[2,6-3H]glucose was determined as previously described (8).
Protein analysis by immunoblotting.
Insulin (10−6 mol/L) or saline were infused in the portal vein, and 90 s later, both portions of gastrocnemius (red and white fibers) were ablated, pooled, minced coarsely, and homogenized immediately in extraction buffer (n = 8), and Western blot was performed, as previously described (9).
Detection of S-nitrosated proteins by biotin switch method.
Data were analyzed by the two-tailed unpaired Student t test or by one-way ANOVA, followed by post hoc analysis of significance (Bonferroni test) when appropriate, comparing experimental and control groups. The level of significance was set at P < 0.05.
To explore the role of iNOS on insulin sensitivity during aging, we analyzed insulin sensitivity in young and old wild-type and iNOS-null male mice. During aging, wild-type and iNOS-null old mice presented similar values for body weight and epididymal fat weight (Fig. 1A and B). High levels of fasting serum insulin levels were found in wild-type old mice but not in iNOS-null mice (Fig. 1C), and fasting blood glucose levels were similar between the groups (data not shown). The hyperinsulinemic-euglycemic clamp revealed that the glucose infusion rate was 13% higher in iNOS-null young mice compared with wild-type young mice (Fig. 1D). In old mice, compared with the respective young group, there was a significant reduction in the insulin sensitivity of control mice compared with iNOS-null mice (Fig. 1D). We observed a strong reduction in the glucose infusion rate in wild-type mice compared with iNOS-null mice after the aging period (Fig. 1E). The reduction in the glucose infusion rate was ∼61% in wild-type mice and ∼31% in iNOS-null mice. Protection against the development of insulin resistance in iNOS-null mice has also been observed in previous studies involving obesity models (12,13).
In addition, we observed that young iNOS-null mice showed higher (15%) insulin-induced glucose uptake in the soleus muscle compared with young wild-type mice (Fig. 1F). In the aged groups, both groups demonstrated impairment in the action of insulin in muscle compared with the respective younger groups (Fig. 1F). However, the variation in the reduction in insulin-induced glucose uptake in the skeletal muscle after aging was more pronounced in wild-type mice than in iNOS-null animals (Fig. 1G). The reduction in the glucose uptake was ∼44% in wild-type mice and ∼21% in iNOS-null mice. In aged animals, iNOS-null mice presented a higher gastrocnemius muscle weight than wild-type mice (169 ± 8.1 vs. 148.2 ± 7.4 mg, P < 0.05).
Western blot analysis showed that aging increased iNOS expression by ∼180% in the skeletal muscle of wild-type mice (Fig. 2A). We also evaluated the expression of the other NOS isoforms and inflammatory markers. Aging reduced endothelial NOS and neuronal NOS expression and increased inhibitor of nuclear factor κ-B (IKKβ) phosphorylation and tumor necrosis factor (TNF)-α expression in wild-type and iNOS-null animals in a similar fashion (Fig. 2A and B). We observed that insulin induced a 10–15% increase in IRβ, IRS-1, and Akt phosphorylation in the muscle of young iNOS-null mice compared with young wild-type animals (Fig. 2C–E). Wild-type mice presented reductions in IRβ, IRS-1, and Akt phosphorylation (43, 71, and 48%, respectively) after aging, whereas the impairment in insulin signaling in the skeletal muscle of iNOS-null mice was relatively minor (18, 22 and 16%, respectively; Fig. 2C–E). In parallel, aging increased IRβ, IRS-1, and Akt S-nitrosation in the muscle of wild-type but not in iNOS-null mice (Fig. 2F and G). In this genetic approach, we demonstrated that iNOS modulates IRβ, IRS-1, and Akt S-nitrosation and insulin sensitivity in the muscle of aged mice, without affecting other NOS isoforms and inflammatory signaling.
To determine whether NO leads to insulin resistance, isolated soleus muscle from young wild-type mice were incubated with increasing NO donor, S-nitrosoglutathione (GSNO). We observed that GSNO reduced insulin-induced glucose uptake in a dose-dependent manner (Fig. 2I). In parallel, GSNO reduced the insulin-induced IRβ, IRS-1, and Akt phosphorylation (Fig. 2J) and markedly increased the S-nitrosation of these proteins (Fig. 2K–M).
To extend our hypothesis, we used pharmacological (L-NIL treatment) and physiological (exercise) approaches to reduce iNOS activity and expression, respectively (14). We observed that neither L-NIL treatment nor exercise changed the total body weight, epididymal fat weight, or fasting insulin serum levels in aged mice compared with aged mice treated with vehicle (Fig. 3A–C). However, the clamp procedure revealed that L-NIL treatment and exercise were able to increase insulin sensitivity in aged mice compared with aged mice treated with vehicle (Fig. 3D). In addition, L-NIL treatment and exercise significantly increased insulin-stimulated glucose uptake in the soleus muscle in old mice (Fig. 3E).
We observed that exercise was able to reduce iNOS and increase endothelial NOS and neuronal NOS expression in the skeletal muscle of aged mice, whereas L-NIL treatment did not change the expression of these enzymes (Fig. 4A and B). In parallel, we observed that L-NIL did not change IKKβ phosphorylation and TNF-α expression, whereas exercise decreased IKKβ phosphorylation and TNF-α expression (Fig. 4C). L-NIL treatment and exercise increase insulin-induced IRβ, IRS-1, and Akt phosphorylation to a similar degree (by ∼45, 130, and 70%, respectively) compared with aged wild-type animals (Fig. 4D–F). In addition, L-NIL treatment and physical exercise reduced age-induced IRβ, IRS-1, and Akt S-nitrosation in the skeletal muscle of aged wild-type mice (Fig. 4G–I).
Here we demonstrated that aging increased iNOS expression, leading to insulin resistance in the skeletal muscle through the S-nitrosation mechanism. Genetic, pharmacological, and physiological iNOS inhibition reduced IRβ, IRS-1, and Akt S-nitrosation and increased insulin signaling in old mice. Our results reinforce the idea that iNOS plays a crucial role in inducing insulin resistance, as previously shown in different animal models such as diet-, lipopolysaccharide-, and lipid-induced skeletal muscle insulin resistance (3,13,15,16).
In contrast to our data, Cha et al. (17) reported that iNOS deficiency does not prevent age-associated insulin resistance. In contrast to the previous study, we did not observe an increase in TNF-α expression in the skeletal muscle of aged iNOS-null mice compared with the aged wild-type group; these data were confirmed by analyzing IKKβ phosphorylation. In accordance with our data, a previous study showed iNOS knockout mice were protected from insulin resistance induced by a high-fat diet (13). Furthermore, iNOS-null mice fed a high-fat diet do not present increased TNF-α levels in the muscle and are protected against lipopolysaccharide-induced S-nitrosation of IRβ/IRS-1 and Akt (12,15).
Accumulating evidence has demonstrated that S-nitrosation negatively modulates insulin signaling (3,5). Our data reveal that high levels of iNOS expression were accompanied by IRβ, IRS-1, and Akt S-nitrosation and insulin resistance in aged male mice. In accordance with our results in male mice, high levels of iNOS expression and IR and Akt S-nitrosation were reported in the liver and adipose tissue of aged female rodents. Altogether, these data suggest that this phenomenon may also occur in female mice (18,19). Wu et al. (20) reported that Akt S-nitrosation was associated with a reduction in Akt activity and with skeletal muscle disorders in aged mice. Although the S-nitrosation of Akt at cysteine 224 leads to inactivation of this kinase, the reactive cysteine residue(s) that undergo(es) S-nitrosation in IR and IRS-1 are unknown and deserve further investigation.
Pharmacological iNOS inhibition has been investigated in animal models of insulin resistance and diabetes. In accordance with the results obtained from aged mice, L-NIL restored insulin sensitivity involving the S-nitrosation mechanism in the muscle of obese rats (3). Beyond the skeletal muscle, high levels of iNOS expression were also reported in the liver of ob/ob mice, whereas L-NIL treatment was sufficient to enhance insulin-induced IRS-1- and IRS-2 phosphorylation (21). Moreover, aspirin treatment improved insulin signaling in the muscle of obese rats by reducing iNOS activity (12). Interestingly, a nonacetylated salicylate treatment, salsalate, also improved glycemic control in diabetic patients in parallel with reductions in the inflammatory response, including reduced levels of serum nitrite, which at least in part may be secondary to reduced iNOS activation (22).
In the current study, we also demonstrated that after a single bout of exercise, iNOS expression and IRβ, IRS-1, and Akt S-nitrosation were diminished; conversely, insulin sensitivity was increased in the skeletal muscle of old mice. These data are in accordance with previous results observed in obese exercised rats (14). Therefore, beyond the pharmacological and genetic approach, the physiological reduction of iNOS levels induced by exercise reversed the deregulation of insulin signaling and insulin resistance observed in old mice.
Beyond S-nitrosation, NO metabolites can also induce tyrosine nitration (i.e., the covalent addition of NO2 to the tyrosine residues of proteins) (23). It has been demonstrated that tyrosine nitration reduces tyrosine phosphorylation and the activation of downstream insulin-signaling intermediates (24). Serine phosphorylation of IRSs mediated by proinflammatory stimuli and increased protein tyrosine phosphatase 1B (PTP1B) activity have been reported as central molecular mechanisms involved in the development of insulin resistance with aging (25). Thus, aging elicits all of these mechanisms, which converge to cause insulin-signaling disruption.
Collectively, our study provides evidence that the age-related increase in muscle iNOS expression and activity is an important contributing factor to the S-nitrosation of insulin signaling proteins and insulin resistance in the skeletal muscle of aged rodents.
This study was supported by grants from Fundacão de Amparo à Pesquisa do Estado de São Paulo and Conselho Nacional de desenvolvimento científico e tecnológico.
No potential conflicts of interest relevant to this article were reported.
E.R.R. researched data and wrote the manuscript. J.R.P., D.E.C., A.S.d.S., C.T.D.S., D.G., B.M.C., A.M.C., C.K.K., M.A.C.-F., and S.H. researched data. R.C. contributed to discussion. L.A.V. and M.J.A.S. contributed to discussion and reviewed and edited the manuscript. J.B.C.C. contributed to discussion and wrote, reviewed, and edited the manuscript. E.R.R. is the guarantor of this work and, as such, had full access to all the data and takes full responsibility for the integrity of data and the accuracy of data analysis.
The authors thank Dr. Marcelo G. de Oliveira from the Chemistry Institute (UNICAMP) for the discussion of some data regarding NO chemical reactions.
See accompanying commentary, p. 346.
- Received March 27, 2012.
- Accepted July 25, 2012.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.